University of North Carolina at Chapel Hill has received two separate grants from the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) today in the ongoing inter-agency partnerships. UNC will accommodate two 14 Tobacco control centers of science (TCORS), which is obtained by a total of up to $ 53 million tobacco-related research in fiscal year 2013.
Center for Regulatory Studies UNC tobacco control connection (CRRTC) will be based at UNC Lineberger Comprehensive Cancer Center. The center will house projects led by Adam Goldstein, MD, MPH, director of the UNC tobacco intervention programs; Noel Brewer, Ph.D., associate professor of health behavior at UNC’s Gillings School of Global Health, and Erin Sutfin, PhD, assistant professor of social sciences and health policy at Wake Forest School of Medicine, and include teachers from the UNC School of Journalism and Mass Communications.
46 faculty, staff and students CRRTC will work on three major studies in strengthening ties with the public about the dangers of alternative tobacco products such as electronic cigarettes, hookahs, and smokeless tobacco, harmful chemicals naturally in tobacco and cigarette smoke, increase confidence to risk and danger to the health of visitors from different ethnic and LGBT people, and how to best communicate FDA authority over tobacco products.
“The goal is to inform and shape how the FDA regulates tobacco products, making high impact study, which will ultimately help reduce the consumption of tobacco,” said Kurt Ribisl, Ph.D., program director for Cancer Prevention and Control Program at UNC Lineberger, a professor of health behavior at the UNC Gillings School of Global Public Health, who will serve as director of the center.
UNC Center for regulation of tobacco and lung health sciences will be based in the School of Medicine and will be directed by Robert Tarran, Ph.D., associate professor of cell biology and physiology. Other projects will be led by Claire Doerschuk, MD, professor of medicine and pathology and director of the UNC respiratory disease; Ilona Jaspers, Ph.D., associate professor of microbiology and immunology and director of educational programs in the field of toxicology, and Mehmet Kesimer, PhD, assistant professor of pathology and medicine. The work of this center is aimed at a better understanding of what components of tobacco and what new and emerging tobacco products have an adverse effect on the hydration of the lungs and of the innate immune defense.
48 faculty, staff and students who make up CTRSLH will work on four separate projects to comprehensively understand how new and emerging tobacco products, such as small cigars and shisha can be harmful to lung health, including chronic bronchitis, impaired innate immunity, tobacco-induced lung inflammation and mucus overproduction.
“Tobacco-induced lung dehydration leads to the disease in more than 12 million Americans with chronic obstructive pulmonary disease (COPD) and more than 64 million people around the world,” said Tarran. “The data obtained in this project will be vital for the direction of the new legislation aimed at limiting the development of new and emerging harmful tobacco products.”
Despite decades of efforts to reduce tobacco use in the United States, it continues to be the leading cause of preventable death and disease. New, first of its kind program for regulating tobacco science, TCORS designed to create research to inform regulation of tobacco products to protect public health. Using funds from the designated FDA, TCORS will be coordinated by the NIH Office of Disease Prevention, directed by David M. Murray, Ph.D., and is controlled by three institutions NIH - National Cancer Institute, the National Institute on Drug Abuse and the National Heart, Lung, and Blood Institute.
“For the first time, under the Prevention of smoking and family Tobacco Control Act, the federal government, through the FDA Center for Tobacco Products (CTP), is able to bring science-based regulation of the production, marketing and distribution of tobacco products,” said FDA Commissioner Margaret A. Hamburg, MD “FDA is committed to evidence-based approach that addresses the complex public health issues raised by the regulation of tobacco products.” Agency of the development of research programs aimed at improving the understanding of the risks associated with tobacco use.
TCORS program brings together researchers from across the country to help in the development and assessment of the situation of tobacco products. Each application TCORS identified targeted research objectives. Taken together, TCORS sites will increase knowledge across the spectrum of fundamental and applied research on tobacco and drug abuse. The program also provides training opportunities to young investigators to ensure the development of the next generation of tobacco regulatory scientists.
“While we have made tremendous strides in reducing tobacco use in the U.S., smoking still accounts for one in five deaths per year, which is too much,” said NIH Director Francis S. Collins, MD, Ph.D. “FDA / NIH partnership as tobacco control centers of science to keep us focused on reducing the burden of disease and devastation caused by tobacco use.”
Consists of scientists with expertise in areas including epidemiology, behavior, biology, medicine, economics, chemistry, toxicology, drug abuse, health care, communications and marketing, TCORS program is the centerpiece of FDA / NIH collaboration to promote research, tobacco-related regulatory science. New research from TCORS help inform and to assess the impact, FDA, current and potential future tobacco regulatory activities carried out under the leadership of CTP Mitch Zeller, JD In addition, TCORS investigators will have the flexibility and the ability to start new research to solve problems in a rapidly growing market of tobacco.
TCORS awards represent a significant investment in the federal tobacco regulatory science, including $ 53 million in the first year and a potential total of more than $ 273 million over the next five years. TCORS funding can not exceed $ 4,000,000 in total costs per year per center, and an investigator of the project may apply for up to five years.
It is intended to form the vital research in seven key areas, as well as providing innovation in the field, the research supported by this initiative will provide scientific data in the following seven FDA tobacco-related areas of research:…